FIRST Trial: Effect of Age on Efficacy and Safety Outcomes in Patients with Newly Diagnosed MM Receiving Rd


FIRST Trial: Effect of Age on Efficacy and Safety Outcomes in Patients with Newly Diagnosed MM Receiving Rd
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Hulin C et al. Effect of age on efficacy and safety outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide and low-dose dexamethasone (Rd): The First trial. Proc ASH 2014;Abstract 81.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.